scholarly journals Retraction Notice

2018 ◽  
Vol 19 (2) ◽  
Author(s):  
Md. Mujibur Rahman
Keyword(s):  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Duplicate Publication ◽  
Retraction Notice

On 10th August 2018 the Editorial Board of Journal of Medicine agreed to retract the article ‘Role of CD 20 in Physiopathology of Hodgkin’s Disease’ published in Journal of Medicine, Vol.19(2) pages 119-122 (DOI: http://dx.doi.org/10.3329/jom.v19i2.37232 ) as it was found to be a duplicate publication of the following published article: ‘CD20 role in pathophysiology of Hodgkin’s disease’ by Marcelo Antônio Oliveira Santos and Marinus de Moraes Lima published in Revista da Associação Médica Brasileira, Vol.63(9) pages 810-813 http://dx.doi.org/10.1590/1806-9282.63.09.810.

scholarly journals Retracted: Role of CD 20 in Physiopathology of Hodgkin’s Disease

2018 ◽  
Vol 19 (2) ◽  
pp. 119-122
Author(s):  
Marcelo Antônio Oliveira Santos
Keyword(s):  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Duplicate Publication ◽  
Retraction Notice

The following retraction notice appears in this issue Vol.19(2) 2018 http://dx.doi.org/10.3329/jom.v19i2.37864On 10th August 2018 the Editorial Board of Journal of Medicine agreed to retract the article ‘Role of CD 20 in Physiopathology of Hodgkin’s Disease’ published in Journal of Medicine, Vol.19(2) pages 119-122 (DOI: https://www.banglajol.info/index.php/JOM/article/view/37232) as it was found to be a duplicate publication of the following published article: ‘CD20 role in pathophysiology of Hodgkin’s disease’ by Marcelo Antônio Oliveira Santos and Marinus de Moraes Lima published in Revista da Associação Médica Brasileira, Vol.63(9) pages 810-813 http://dx.doi.org/10.1590/1806-9282.63.09.810.J MEDICINE JUL 2018; 19 (2) : 119-122

Study of the HLA-DPβ1 Locus by the Polymerase Chain Reaction Technique in Patients with Hodgkin's Disease

1993 ◽  
Vol 79 (2) ◽  
pp. 133-136 ◽  
Author(s):  
Guseppe Pellegris ◽  
Claudia Lombardo ◽  
Annelisa Cantoni ◽  
Liliana Devizzi ◽  
Monica Balzarotti
Keyword(s):  
Polymerase Chain Reaction ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Polymerase Chain Reaction Method ◽  
Healthy Controls ◽  
Chain Reaction ◽  
Reaction Method ◽  
Significant Difference ◽  
Polymerase Chain

Background A number of reports have studied associations between Hodgkin's disease and HLA. Some of them established correlation between several antigens and Hodgkin's disease, and others found no correlations. Methods The HLA DP locus was determined by the polymerase chain reaction method in 31 Hodgkin's disease patients and 58 healthy controls. Results No significant difference between patients and controls was noted. Conclusions Further investigations are needed to confirm the hypothesis of a possible role of the HLA complex as one of the factors involved in Hodgkin's disease.

Successful marrow transplantation for acute myelocytic leukemia following therapy for Hodgkin's disease.

1988 ◽  
Vol 6 (10) ◽  
pp. 1558-1561 ◽  
Author(s):  
R B Geller ◽  
G B Vogelsang ◽  
J R Wingard ◽  
A M Yeager ◽  
W H Burns ◽  
...  
Keyword(s):  
Hodgkin's Disease ◽  
Marrow Transplantation ◽  
Hematologic Malignancy ◽  
Hodgkin’S Disease ◽  
Combined Modality Therapy ◽  
Intensive Therapy ◽  
Acute Myelocytic Leukemia ◽  
Myelocytic Leukemia ◽  
Histocompatibility Locus

Five patients with acute myelocytic leukemia (AML) after combined modality therapy for Hodgkin's disease (HD) were treated with cyclophosphamide and busulfan followed by bone marrow transplantation (BMT). Four patients received allogeneic transplants from histocompatibility locus antigen (HLA)-compatible siblings and the fifth patient received an autologous marrow treated with 4-hydroperoxycyclophosphamide. Two patients died of complications of acute graft-v-host disease (GVHD) despite prophylaxis with either low-dose cyclophosphamide or cyclosporine. The remaining three patients were alive and disease-free 382, 617, and 620 days after transplant. These initial results are encouraging and more patients with treatment-related AML need to be evaluated with both allogeneic and autologous BMT to fully elucidate the potentially curative role of this intensive therapy in an otherwise fatal hematologic malignancy.

Lung Cancer After Hodgkin’s Disease: A Nested Case-Control Study of the Relation to Treatment

2001 ◽  
Vol 19 (6) ◽  
pp. 1610-1618 ◽  
Author(s):  
A. J. Swerdlow ◽  
M. J. Schoemaker ◽  
R. Allerton ◽  
A. Horwich ◽  
J. A. Barber ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Hodgkin's Disease ◽  
Case Control Study ◽  
Hodgkin’S Disease ◽  
Case Control ◽  
Lung Cancers ◽  
Number Of Cycles ◽  
Nested Case Control ◽  
Control Study

PURPOSE: To investigate the causes of the raised risk of lung cancer in patients who have had Hodgkin’s disease, and in particular the relationship to treatment. PATIENTS AND METHODS: A nested case-control study was conducted within a cohort of 5,519 patients with Hodgkin’s disease treated in Britain during 1963 through 1993. For 88 cases of lung cancer and 176 matched control subjects, information on treatment and other risk factors was extracted from hospital case-notes, and odds ratios for lung cancer in relation to these factors were calculated. RESULTS: Risk of lung cancer was borderline significantly greater in patients treated with mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) chemotherapy than those who did not receive this treatment (relative risk [RR] = 1.66; 95% confidence interval [CI], 0.99 to 2.82), and increased with number of cycles of MOPP (P = .07). Exclusion of lung cancers for which histologic confirmation was not available strengthened these associations (RR = 2.41; 95% CI, 1.33 to 4.51; P = .004 for any MOPP and P = .007 for trend with number of cycles of MOPP). Risks were not raised, however, after chlorambucil, vinblastine, procarbazine, and prednisone treatment. There was evidence that the raised risk of lung cancer occurring in relation to radiotherapy was restricted to histologies other than adenocarcinoma. CONCLUSION: The results suggest that MOPP chemotherapy may lead to elevated risk of lung cancer, at least in certain subgroups of patients. The role of chemotherapy in the etiology of lung cancer after Hodgkin’s disease deserves further investigation.

Sign in / Sign up

Export Citation Format

Share Document